Compare Summit Therapeutics Inc (SMMT) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Vale SA — how do they compare? Summit Therapeutics Inc trades at $15.21 (market cap $12.06B), while Vale SA trades at $14.45 (market cap $61.97B). The key difference: Vale SA is far larger — about 5.1× Summit Therapeutics Inc's market cap, and Vale SA pays a 8.35% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | VALE | |
|---|---|---|
Market Cap | $12.06B | $61.97B |
Sector | Health | Basic Materials |
52-Week High | $26.98 | $17.82 |
52-Week Low | $12.55 | $9.71 |
Enterprise Value | $11.39B | $78.22B |
Dividend Yield | — | 8.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
VALE trades at $14.49, down 2.72% with a bearish technical outlook. Recent earnings missed expectations for three consecutive quarters, with Q3 2026 results pending. The company maintains strong cash flow generation ($8.8B operating cash flow in 2025) and a 5.11% net margin, though profitability has declined from 2022 peaks. Analyst consensus is mixed with 38% Buy ratings and a $16.79 price target, representing 16% upside potential.
VALE offers value with reasonable valuations (P/E 28.6, P/B 1.6) and dividend yield, but faces headwinds from rising costs and earnings volatility. The stock's near-term trajectory depends on Q3 earnings delivery and copper segment execution. Key risks include commodity price sensitivity and operational challenges in base metals expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
